GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » 5-Day RSI

Laekna (HKSE:02105) 5-Day RSI : 45.68 (As of May. 28, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Laekna 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-05-28), Laekna's 5-Day RSI is 45.68.

The industry rank for Laekna's 5-Day RSI or its related term are showing as below:

HKSE:02105's 5-Day RSI is ranked worse than
60.18% of 1567 companies
in the Biotechnology industry
Industry Median: 40.5 vs HKSE:02105: 45.68

Competitive Comparison of Laekna's 5-Day RSI

For the Biotechnology subindustry, Laekna's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laekna's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Laekna's 5-Day RSI falls into.



Laekna  (HKSE:02105) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laekna  (HKSE:02105) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Laekna 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Laekna's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Laekna (HKSE:02105) Business Description

Traded in Other Exchanges
N/A
Address
No. 987, Cailun Road, 5th Floor, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Liu Zeng 2201 Interest of corporation controlled by you
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Si Mu Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yao Shang Yan Chuang Shou Ren Gu Quan Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Yan Chuang Hou De Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Chun Lin Xin Xi Zi Xun Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing An Long Chuang Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Liu Ying 2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Futu Trustee Limited 2301 Trustee

Laekna (HKSE:02105) Headlines

No Headlines